LMAT icon

LeMaitre Vascular

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 40%
Negative

Neutral
GlobeNewsWire
5 days ago
LeMaitre Will Announce Third Quarter 2025 Earnings Results on November 6, 2025
BURLINGTON, Mass., Oct. 09, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its third quarter 2025 financial results on Thursday, November 6, 2025, after the market close.
LeMaitre Will Announce Third Quarter 2025 Earnings Results on November 6, 2025
Positive
Seeking Alpha
29 days ago
LeMaitre Vascular: Investment Debate Remains In Place
LeMaitre Vascular remains a long-term compounder, delivering strong Q2 results with 15% sales growth, robust margins, and increased dividends. LMAT's investment thesis is supported by pricing power, an expanding product pipeline, disciplined capital allocation, and consistent reinvestment driving high returns on capital. Valuation is fair-to-full at current levels, with a $110-$111 price target; compounding will come from intrinsic value growth rather than multiple expansion.
LeMaitre Vascular: Investment Debate Remains In Place
Neutral
GlobeNewsWire
1 month ago
LeMaitre to Participate at Upcoming Investor Conferences in September
BURLINGTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in four upcoming investor conferences.
LeMaitre to Participate at Upcoming Investor Conferences in September
Positive
Zacks Investment Research
1 month ago
Is LeMaitre (LMAT) a Solid Growth Stock? 3 Reasons to Think "Yes"
LeMaitre (LMAT) possesses solid growth attributes, which could help it handily outperform the market.
Is LeMaitre (LMAT) a Solid Growth Stock? 3 Reasons to Think "Yes"
Positive
Zacks Investment Research
2 months ago
LeMaitre (LMAT) is an Incredible Growth Stock: 3 Reasons Why
LeMaitre (LMAT) is well positioned to outperform the market, as it exhibits above-average growth in financials.
LeMaitre (LMAT) is an Incredible Growth Stock: 3 Reasons Why
Positive
The Motley Fool
2 months ago
LeMaitre (LMAT) Q2 Revenue Jumps 15%
LeMaitre (LMAT) Q2 Revenue Jumps 15%
LeMaitre (LMAT) Q2 Revenue Jumps 15%
Neutral
Seeking Alpha
2 months ago
LeMaitre Vascular, Inc. (LMAT) Q2 2025 Earnings Call Transcript
LeMaitre Vascular, Inc. (NASDAQ:LMAT ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants David B. Roberts - President & Director Dorian LeBlanc - Chief Financial Officer George W.
LeMaitre Vascular, Inc. (LMAT) Q2 2025 Earnings Call Transcript
Positive
Zacks Investment Research
2 months ago
LeMaitre Vascular (LMAT) Beats Q2 Earnings and Revenue Estimates
LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.6 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.52 per share a year ago.
LeMaitre Vascular (LMAT) Beats Q2 Earnings and Revenue Estimates
Neutral
GlobeNewsWire
2 months ago
LeMaitre Q2 2025 Financial Results
BURLINGTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q2 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance.
LeMaitre Q2 2025 Financial Results
Positive
Zacks Investment Research
2 months ago
PAHC vs. LMAT: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical - Products stocks have likely encountered both Phibro Animal Health (PAHC) and LeMaitre Vascular (LMAT). But which of these two stocks presents investors with the better value opportunity right now?
PAHC vs. LMAT: Which Stock Should Value Investors Buy Now?